Interaction
15
3
4
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.7%
1 terminated out of 15 trials
90.0%
+3.5% vs benchmark
0%
0 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters
COPE Program , Mental Health, Mother- Infant Interaction, Sense of Competence
System Dynamics Model for Acute Non-contact Lower Extremity Injuries Prediction
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
Integration of Tai Chi and Repetitive Transcranial Magnetic Stimulation for Sleep Disturbance in Older Adults
COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer
Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis
Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol
The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants
The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers
Walking the Isobole of Drug Interaction
The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers
-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms